Search Results 131-140 of 18341 for alopecia

  1. A Study to Evaluate Ribociclib Plus Letrozole to Treat Cancer of the Ovary, Fallopian Tube or Peritoneum - Mayo Clinic

    ... alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated. Patient has had major surgery within 14 days prior to starting study drug or ...

  2. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

    Persistent clinically significant ≥ Grade 2 toxicities from previous chemotherapy (excluding alopecia, nausea, fatigue, anemia, and liver function tests [as ...

  3. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

    Subjects must not have unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer therapy, except for alopecia or anemia. Subjects ...

  4. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation - Mayo Clinic

    Patients with vitiligo or alopecia; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; Any chronic skin ...

  5. Vitiligo - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Diffuse capillary malformation with overgrowth, Vulvar skin disorder, Blue rubber bleb nevus syndrome, Vascular anomaly, Vascular ...

  6. Study of bb2121 in Multiple Myeloma - Clinical Trials

    Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. * True abstinence ...

  7. A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma - Mayo Clinic

    ... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...

  8. Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers - Mayo Clinic

    0 for phase II part 2 (except neuropathy [see exclusion criterion below] and alopecia). Neuropathy ≥ Grade 3. Clinically significant (that is, active) ...

  9. Rosacea - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...

  10. Tinea versicolor - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...